Evidence map›Paper›PMID 25896322›Full record

ArticleNature2015

Intrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells.

Edward J Grow, Ryan A Flynn, Shawn L Chavez, Nicholas L Bayless, Mark Wossidlo, Daniel J Wesche, Lance Martin, Carol B Ware, Catherine A Blish, Howard Y Chang and 2 more

Abstract read
In one paragraph

Article in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 377 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
377citing papers in PubMed, 1 pooled it
96.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

377 citing papers in PubMed, 1 synthesis or guideline pooled it, 656 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Evolution ofInternational journal of molecular sciences · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. A cross-talk between p16High senescence and cellular reprogramming.Clinical science (London, England : 1979) · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

317 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Edward J GrowDepartment of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA.
Ryan A FlynnHoward Hughes Medical Institute and Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Shawn L Chavez1] Institute for Stem Cell Biology &Regenerative Medicine, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA [2] Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA [3] Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, Oregon Health &Science University, Beaverton, Oregon 97006, USA.
Nicholas L BaylessStanford Immunology, Stanford University School of Medicine, Stanford, California 94305, USA.
Mark Wossidlo1] Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA [2] Institute for Stem Cell Biology &Regenerative Medicine, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA [3] Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA.
Daniel J WescheInstitute for Stem Cell Biology &Regenerative Medicine, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA.
Lance MartinHoward Hughes Medical Institute and Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Carol B WareDepartment of Comparative Medicine, University of Washington, Seattle, Washington 98195-8056, USA.
Catherine A BlishDepartment of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA.
Howard Y ChangHoward Hughes Medical Institute and Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Renee A Reijo Pera1] Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA [2] Institute for Stem Cell Biology &Regenerative Medicine, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA [3] Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA [4] Department of Cell Biology and Neurosciences, Montana State University, Bozeman, Montana 59717, USA.
Joanna Wysocka1] Institute for Stem Cell Biology &Regenerative Medicine, Stanford University School of Medicine, Stanford University, Stanford, California 94305, USA [2] Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305, USA [3] Department of Developmental Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Stanford University · USHoward Hughes Medical Institute · USUniversity of Washington · US

Funding

INSTITUTIONAL TRAINING GRANT IN GENOME SCIENCET32HG000044 · NHGRI · STANFORD UNIVERSITY · PI MICHAEL P. SNYDER · 1995 to 2026
$32.2M
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
Special EquipmentP50HG007735 · NHGRI · STANFORD UNIVERSITY · PI CHANG, HOWARD Y · 2014 to 2018
$15.2M
Project 3: Effect of Age and Longevity Genes on Epigenomic MechanismsP01GM099130 · NIGMS · STANFORD UNIVERSITY · PI WYSOCKA, JOANNA · 2011 to 2015
$11.4M
Basic and Translational Research iPSC-based hematologic and vascular therapiesU01HL100397 · NHLBI · STANFORD UNIVERSITY · PI COOKE, JOHN P · 2009 to 2015
$7.4M
Modeling the influence of sex on natural killer cell networksDP2AI112193 · NIAID · STANFORD UNIVERSITY · PI BLISH, CATHERINE A · 2013 to 2015
$2.5M
Mechanisms of enhancer activation in early developmentR01GM112720 · NIGMS · STANFORD UNIVERSITY · PI WYSOCKA, JOANNA · 2015 to 2018
$1.2M
CONTROL OF TRANSCRIPTION BY THE 7SK RNA IN BREAST CANCERF30CA189514 · NCI · STANFORD UNIVERSITY · PI FLYNN, RYAN ALEXANDER · 2014 to 2015
$96k
Howard Hughes Medical InstituteNCI NIH HHS 1F30CA189514-01NCI NIH HHS F30 CA189514NCRR NIH HHS 1S10RR02678001NCRR NIH HHS 1S10RR02933801NHGRI NIH HHS P50 HG007735NHGRI NIH HHS P50-HG007735NHGRI NIH HHS T32 HG000044NHLBI NIH HHS U01 HL100397NIAID NIH HHS DP2 AI112193NIAID NIH HHS DP2AI11219301NIGMS NIH HHS P01 GM099130NIGMS NIH HHS P01GM099130NIGMS NIH HHS R01 GM112720
6 · The paper itself

Abstract

Endogenous retroviruses (ERVs) are remnants of ancient retroviral infections, and comprise nearly 8% of the human genome. The most recently acquired human ERV is HERVK(HML-2), which repeatedly infected the primate lineage both before and after the divergence of the human and chimpanzee common ancestor. Unlike most other human ERVs, HERVK retained multiple copies of intact open reading frames encoding retroviral proteins. However, HERVK is transcriptionally silenced by the host, with the exception of in certain pathological contexts such as germ-cell tumours, melanoma or human immunodeficiency virus (HIV) infection. Here we demonstrate that DNA hypomethylation at long terminal repeat elements representing the most recent genomic integrations, together with transactivation by OCT4 (also known as POU5F1), synergistically facilitate HERVK expression. Consequently, HERVK is transcribed during normal human embryogenesis, beginning with embryonic genome activation at the eight-cell stage, continuing through the emergence of epiblast cells in preimplantation blastocysts, and ceasing during human embryonic stem cell derivation from blastocyst outgrowths. Remarkably, we detected HERVK viral-like particles and Gag proteins in human blastocysts, indicating that early human development proceeds in the presence of retroviral products. We further show that overexpression of one such product, the HERVK accessory protein Rec, in a pluripotent cell line is sufficient to increase IFITM1 levels on the cell surface and inhibit viral infection, suggesting at least one mechanism through which HERVK can induce viral restriction pathways in early embryonic cells. Moreover, Rec directly binds a subset of cellular RNAs and modulates their ribosome occupancy, indicating that complex interactions between retroviral proteins and host factors can fine-tune pathways of early human development.

Indexed as

Virus ActivationAntigens, DifferentiationBlastocystCell LineDNA MethylationEndogenous RetrovirusesFemaleGene Products, gagHumansMaleOctamer Transcription Factor-3Open Reading FramesPluripotent Stem CellsRibosomesRNA, MessengerTerminal Repeat SequencesAntigens, DifferentiationERVK-6 protein, human endogenous retrovirusGene Products, gagleu-13 antigenOctamer Transcription Factor-3POU5F1 protein, humanRNA, MessengerViral Envelope Proteins

Identifiers

PMID25896322
PMCPMC4503379
OpenAlexW2068878293

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.